• Image 01
  • Image 02
  • Image 03
  • Image 04
  • Image 05
  • Image 06
Need assistance? Contact Us: 1-800-255-5897

Menu

  • Home
  • About Us
    • Company Overview
    • Management Team
    • Board of Directors
  • Your Loan Service Center
  • MAKE A PAYMENT
  • Business Service Center
  • Contact Us
  • Home
  • About Us
    • Company Overview
    • Management Team
    • Board of Directors
  • Your Loan Service Center
  • MAKE A PAYMENT
  • Business Service Center
  • Contact Us
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Gilead Sciences (NQ: GILD )

89.51 +0.69 (+0.78%)
Streaming Delayed Price Updated: 4:00 PM EDT, Nov 1, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 6,485,876
Open 88.31
Bid (Size) 89.30 (1)
Ask (Size) 89.50 (1)
Prev. Close 88.82
Today's Range 88.19 - 89.57
52wk Range 62.07 - 89.74
Shares Outstanding 1,253,809,440
Dividend Yield 3.35%
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
AbTherx and Gilead Expand Collaboration on Innovative Antibody Discovery Technologies
October 31, 2024
Via ACCESSWIRE
Lyell Immunopharma Downgraded, Analyst Flags Concerns Over Acquisition Strategy
October 30, 2024
Lyell Immunopharma acquires ImmPACT Bio, ends TIL programs, and refocuses on CAR T-cell research. Analyst downgrades reflect concerns over pipeline complexities. 
Via Benzinga

Performance

YTD
+7.53%
+7.53%
1 Month
+6.34%
+6.34%
3 Month
+19.62%
+19.62%
6 Month
+36.57%
+36.57%
1 Year
+9.71%
+9.71%

More News

Read More
3 Absurdly Cheap Stocks That Pay High Dividends
October 24, 2024
Via The Motley Fool
Healthcare Sector Update: Choppy Days Are Here Again As Yields Rise
October 22, 2024
Via Talk Markets
Gilead to Present Latest Research Across Key Liver Disease Indication at the American Association for the Study of Liver Disease (AASLD) Meeting 2024
October 22, 2024
From Gilead Sciences, Inc.
Via Business Wire
Peering Into Gilead Sciences's Recent Short Interest
October 21, 2024
Via Benzinga
Evaluating Gilead Sciences: Insights From 15 Financial Analysts
October 21, 2024
Via Benzinga
Gilead Sciences/Merck's Investigational Once-Weekly HIV Combo Therapy Shows Sustained Virus Suppression To 48 Weeks
October 21, 2024
Via Benzinga
Robinhood To Rally Around 12%? Here Are 10 Top Analyst Forecasts For Monday
October 21, 2024
Via Benzinga
This JD.com Analyst Turns Bullish; Here Are Top 5 Upgrades For Monday
October 21, 2024
Via Benzinga
Gilead and Merck Announce Phase 2 Data Showing a Treatment Switch to an Investigational Oral Once-Weekly Combination Regimen of Islatravir and Lenacapavir Maintained Viral Suppression in Adults at Week 48
October 19, 2024
From Gilead Sciences, Inc.
Via Business Wire
Here's How Much $100 Invested In Gilead Sciences 20 Years Ago Would Be Worth Today
October 17, 2024
Via Benzinga
Will GILEAD SCIENCES INC breakout?
October 14, 2024
Via Chartmill
Peeling Back The Layers: Exploring Gilead Sciences Through Analyst Insights
October 04, 2024
Via Benzinga
After Failed Confirmatory Trial, Gilead Withdraws US Accelerated Approval Of Trodelvy As Bladder Cancer treatment
October 18, 2024
Via Benzinga
This Gilead Sciences Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Thursday
October 17, 2024
Via Benzinga
Gilead Sciences to Release Third Quarter 2024 Financial Results on Wednesday, November 6, 2024
October 09, 2024
From Gilead Sciences, Inc.
Via Business Wire
Biden Administration Unveils Plan To Provide Generic Drugs for $2 to Medicare Recipients
October 09, 2024
Via Benzinga
$1000 Invested In This Stock 20 Years Ago Would Be Worth $8,800 Today
October 01, 2024
Via Benzinga
Gilead to Present Late-Breaking Data Highlighting Antiviral Portfolio, Innovative Research Pipeline and HIV Leadership at IDWeek 2024
October 09, 2024
From Gilead Sciences, Inc.
Via Business Wire
Biotech Stocks Poised For Another Big Move In Q4
October 07, 2024
Via Talk Markets
Gilead Presents Additional Efficacy, Safety and Demographic Data From PURPOSE 2 Trial at 5th HIV Research for Prevention Conference
October 07, 2024
From Gilead Sciences, Inc.
Via Business Wire
S&P 500 Could Reach 6,300 In 12 Months, Says Goldman Sachs, Driven By 'Strong AI Demand' And 'Margin Expansion'
October 07, 2024
Via Benzinga
Topics Artificial Intelligence Stocks
Exposures Artificial Intelligence US Equities
Wall Street's Most Accurate Analysts Spotlight On 3 Health Care Stocks Delivering High-Dividend Yields
October 07, 2024
Via Benzinga
Gilead Signs Royalty-Free Voluntary Licensing Agreements With Six Generic Manufacturers to Increase Access to Lenacapavir for HIV Prevention in High-Incidence, Resource-Limited Countries
October 02, 2024
From Gilead Sciences, Inc.
Via Business Wire
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.

Having difficulty making your payments? We're here to help! Call 1-800-255-5897

Copyright © 2019 Franklin Credit Management Corporation
All Rights Reserved
Contact Us | Privacy Policy | Terms of Use | Sitemap